A Study of the Safety and Efficacy of Nitric Oxide Reduction in Patients With Cardiogenic Shock After a Heart Attack
Status:
Terminated
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
Tilarginine Acetate Injection is a new type of drug that temporarily stops the body from
making a bodily substance called nitric oxide. The body may produce excess nitric oxide
following severe heart damage leading to shock. During a heart attack, and especially after a
blocked artery causing the heart attack is reopened, a large amount of nitric oxide is
released into the heart muscle and into the blood. Normally small amounts of nitric oxide are
good for the heart and blood vessels. However, when released in large amounts, such as during
a heart attack, it may be harmful, by adding to the damage of the heart attack and lowering
the heart's ability to pump blood to the body. It may cause blood pressure to be lowered and
reduce the amount of blood flow to the body's vital organs. This may interfere with the
body's organs being able to do their work. If Tilarginine Acetate Injection can stop extra
nitric oxide from being made, the performance of the heart and blood flow to the organs may
get better, which may result in the improvement of symptoms. The purpose of this study
(TRIUMPH) is to investigate the safety and effectiveness of Tilarginine Acetate Injection
compared to placebo (an inactive fluid that has no effect on the body but looks exactly like
the medication being studied). The study will help determine whether Tilarginine Acetate
Injection, by temporarily lowering the amount of nitric oxide released into the vital organs
can improve blood pressure and the blood flow to the body's organs.